复方制剂策略：心血管疾病预防的范式转变。 - Suppr

Suppr

超能文献

Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention.

作者信息

Akbar Makhzan Ali, Batool Asia, Khawar Muneeb, Dero Abdul Manan, Iqbal Javed

机构信息

North Sichuan Medical College, Nanchong, China.

Sir Syed College of Medical Sciences, Karachi, Pakistan.

出版信息

Am J Cardiovasc Drugs. 2025 Aug 13. doi: 10.1007/s40256-025-00758-5.

DOI:10.1007/s40256-025-00758-5

PMID:40802150

Abstract

摘要

相似文献

Polypill Strategy: A Paradigm Shift in Cardiovascular Disease Prevention.

Am J Cardiovasc Drugs. 2025 Aug 13. doi: 10.1007/s40256-025-00758-5.

Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.

Vasc Health Risk Manag. 2023 Sep 12;19:605-615. doi: 10.2147/VHRM.S421024. eCollection 2023.

Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial.

Lancet Reg Health Eur. 2025 Jun 27;55:101348. doi: 10.1016/j.lanepe.2025.101348. eCollection 2025 Aug.

Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population.

JAMA Cardiol. 2025 Mar 1;10(3):224-233. doi: 10.1001/jamacardio.2024.4812.

Efficacy of different polypill combinations for primary and secondary cardiovascular disease prevention: a systematic review and meta-analysis.

Front Cardiovasc Med. 2025 Jun 9;12:1558579. doi: 10.3389/fcvm.2025.1558579. eCollection 2025.

Stakeholder Perspectives on a Heart Failure With Reduced Ejection Fraction Polypill: A Multi-Center Mixed Methods Study.

Circ Cardiovasc Qual Outcomes. 2024 Nov;17(11):e011121. doi: 10.1161/CIRCOUTCOMES.124.011121. Epub 2024 Nov 6.

Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials.

Curr Probl Cardiol. 2023 Aug;48(8):101735. doi: 10.1016/j.cpcardiol.2023.101735. Epub 2023 Apr 11.

Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.

Circ Cardiovasc Qual Outcomes. 2015 May;8(3):301-8. doi: 10.1161/CIRCOUTCOMES.115.001483. Epub 2015 May 5.

Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials.

J Cardiovasc Pharmacol. 2024 Jan 1;83(1):8-15. doi: 10.1097/FJC.0000000000001508.

Polypill for cardiovascular disease prevention: Systematic review and meta-analysis of randomized controlled trials.

Int J Cardiol. 2022 Aug 1;360:91-98. doi: 10.1016/j.ijcard.2022.04.085. Epub 2022 May 6.

本文引用的文献

Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population.

JAMA Cardiol. 2025 Mar 1;10(3):224-233. doi: 10.1001/jamacardio.2024.4812.

Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars).

Heart. 2024 Jun 25;110(14):940-946. doi: 10.1136/heartjnl-2023-323614.

The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.

Curr Cardiol Rev. 2024;20(2):61-71. doi: 10.2174/011573403X283174240110025442.

Redefining the polypill: pros and cons in cardiovascular precision medicine.

Front Pharmacol. 2023 Sep 19;14:1268119. doi: 10.3389/fphar.2023.1268119. eCollection 2023.

Polypill-based strategy vs. usual care for secondary prevention of cardiovascular disease: a meta-analysis of randomized controlled trials.

Eur J Prev Cardiol. 2023 Nov 9;30(16):1828-1837. doi: 10.1093/eurjpc/zwad245.

Meta-Analysis on the Clinical Outcomes With Polypills for Cardiovascular Disease Prevention.

Am J Cardiol. 2023 Aug 15;201:211-218. doi: 10.1016/j.amjcard.2023.06.001. Epub 2023 Jun 27.

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).

J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26.

Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.

PLoS One. 2022 Jul 28;17(7):e0271908. doi: 10.1371/journal.pone.0271908. eCollection 2022.

A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.

J Hypertens. 2020 Oct;38(10):1890-1898. doi: 10.1097/HJH.0000000000002464.

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验